RCT: Therapeutic drug monitoring during infliximab induction does not improve disease remission in patients with chronic immune-mediated inflammatory diseases

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

Commentary on Twitter

Study findings do not support routine use of proactive therapeutic drug monitoring during infliximab induction for improving immune-mediated inflammatory disease remission rates https://t.co/sDslkVm3u9

— JAMA (@JAMA_current) May 5, 2021